Laboratorios Cinfa is a leading Spanish pharmaceutical founded in 1969 and headquartered in Navarra. The company has more than 170 active ingredients and work in 12 therapeutic areas ranging from the most common and well-known treatments, such as ibuprofen, to highly specialized treatments, mainly dedicated to the areas of oncology and transplants.
The company leads the generics market by units dispensed in pharmacies and one out of every five generic drugs in Spanish homes is from Cinfa according to IQVIA.
As general manager of Mundipharma Spain & Portugal since 2007, Alberto Martínez has been witness to an interesting evolution of Spain’s pharma industry during some tough times. He talks about…
Prior to joining the family business, Ignasi Biosca spent his career working in online media and internet advertising. Upon becoming CEO of Reig Jofre in 2007, he quickly sought to…
Xavi Martí, managing director of Lundbeck Spain, discusses how the affiliate responds to the challenge of social stigma surrounding mental diseases and new strategies to open up the company’s portfolio…
Key to improve the Chilean health care system is providing continuous training programs and sharing knowledge with healthcare professionals”, explains Cécile Bassereau, Managing Director B Braun Chile. B. Braun has…
As a leading company in the hospital sector, Roche Spain undoubtedly felt the effects of austerity measures imposed by Spanish health authorities since 2010. Nevertheless, the affiliate has remained in…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Owned completely by the LEO Foundation, LEO Pharma is an extremely patient-centric company focused primarily in the dermatology area. Kristian Hart-Hansen, general manager of LEO Pharma Spain, discusses the challenges…
In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains…
In a market dogged by price cuts and changes in regulations, the challenges for blood plasma companies have become graver than ever. In spite of these challenges, CSL Behring remains…
Raúl Díaz-Varela is the CEO of Kern Pharma and has served as president of Spain’s generics association AESEG since 2008. He speaks to us about the challenges facing generic companies,…
Jesús Sobrino was appointed general manager of UCB Iberia in 2010, at the same time the pharma market began to seriously contract in Spain. Sobrino discusses adapting to these changes…
PharmaBoardroom first interviewed Erik Lommerde as general manager of Novo Nordisk Netherlands four years ago. In his new role as general manager of Novo Nordisk Spain & Portugal, he discusses…
See our Cookie Privacy Policy Here
